BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

Rhea-AI Summary

AtaiBeckley (NASDAQ: ATAI) said it remains on track to start two parallel Phase 3 studies of BPL-003 in Q2 2026 after a successful End-of-Phase 2 meeting with the FDA. BPL-003 holds Breakthrough Therapy Designation and showed rapid Day 2 antidepressant effects and durable improvements through eight weeks in Phase 2b.

The company reaffirmed cash runway into early 2029, outlined a scalable commercial model aligned with interventional psychiatry workflows, noted positive Phase 2a results for EMP-01, and expects VLS-01 Phase 2 topline in H2 2026.

Positive

• BPL-003 advanced to Phase 3 initiation on track for Q2 2026
• BPL-003 holds Breakthrough Therapy Designation
• Phase 2b showed rapid Day 2 antidepressant effects and durability to eight weeks
• Cash runway reaffirmed into early 2029
• Commercial model aligned to existing interventional psychiatry workflows (Spravato®-compatible)

Negative

• Phase 3 timeline depends on successful initiation and execution of two large pivotal studies
• No financial guidance or revenue metrics disclosed to quantify commercial forecast
• VLS-01 Phase 2 topline expected in H2 2026; outcome uncertainty may affect near-term pipeline visibility

Key Figures

Phase 3 initiation timing: Q2 2026 Core study duration: 12 weeks Extension duration: 52 weeks +5 more

8 metrics

Phase 3 initiation timing Q2 2026 Planned start of two parallel Phase 3 BPL‑003 TRD trials

Core study duration 12 weeks Randomized, double-blind, placebo-controlled Phase 3 core period

Extension duration 52 weeks Open-label extension with individualized retreatment

BPL-003 effect window Day 2 Rapid antidepressant effects observed after a single dose in Phase 2b

Initial durability Eight weeks Improvements maintained up to eight weeks post initial dose

Second-dose durability Further eight weeks Improved response and remission sustained after second OLE dose

VLS-01 Phase 2 topline H2 2026 Expected Phase 2 topline readout timing for VLS-01

Cash runway horizon Early 2029 Management reaffirms funding runway through planned Phase 3 topline

Market Reality Check

Price: $3.89 Vol: Volume 9,115,790 is 1.86x...

high vol

$3.89 Last Close

Volume Volume 9,115,790 is 1.86x the 20-day average, signaling elevated interest around the news. high

Technical Shares at $3.89 are trading slightly below the 200-day MA of $3.97, despite a 14.75% move.

Peers on Argus

ATAI gained 14.75% while key peers showed relatively modest moves (e.g., QURE up...

1 Up

ATAI gained 14.75% while key peers showed relatively modest moves (e.g., QURE up 6.84%, others near flat). With only one peer in the momentum scan and mixed moves across ATNF, SYRE, VERV, this reaction appears stock-specific rather than a broad biotech or psychiatry-sector move.

Previous Clinical trial Reports

5 past events · Latest: Mar 03 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	End-of-Phase 2 update	Positive	+0.3%	FDA backed dual pivotal Phase 3 program for BPL‑003 in TRD.
Feb 26	Phase 2a topline	Positive	-14.1%	EMP‑01 Phase 2a in social anxiety met safety and showed efficacy signals.
Nov 10	Phase 2b OLE data	Positive	-0.2%	BPL‑003 OLE showed sustained antidepressant benefit and supportive safety.
Jul 25	Trial did not meet endpoint	Negative	-6.7%	Inidascamine Phase 2b in CIAS missed primary endpoint despite safety profile.
Jul 01	Phase 2b topline	Positive	+23.7%	BPL‑003 Phase 2b in TRD met primary and key secondary endpoints.

Pattern Detected

Clinical updates have produced mixed reactions: some strong rallies on positive data alongside several selloffs or muted moves, indicating inconsistent trading response to trial news.

Recent Company History

Over the past year, ATAI’s key catalyst path has centered on BPL‑003 and broader CNS programs. Positive Phase 2b data in July 2025 drove a strong move, followed by supportive BPL‑003 OLE data in November 2025. A failed inidascamine endpoint in July 2025 weighed on shares. More recently, positive EMP‑01 Phase 2a results and a successful BPL‑003 End‑of‑Phase 2 FDA meeting in February–March 2026 laid the groundwork for the current Phase 3–focused update.

Historical Comparison

+0.6% avg move · In the past 12 months, ATAI released 5 clinical-trial updates averaging a 0.6% move. Today’s 14.75% ...

clinical trial

+0.6%

Average Historical Move clinical trial

In the past 12 months, ATAI released 5 clinical-trial updates averaging a 0.6% move. Today’s 14.75% reaction to advancing BPL‑003 toward dual Phase 3 trials stands out versus prior, often muted or mixed responses.

Clinical news shows a clear BPL‑003 progression: positive Phase 2b topline in July 2025, supportive OLE data in November 2025, then a successful End‑of‑Phase 2 FDA meeting in March 2026, now followed by a Phase 3 initiation plan for Q2 2026.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-29

ATAI has an effective S-3ASR filed on September 29, 2025 registering securities for resale. The shelf is currently active and has been used in at least 3 prospectus supplements dated October–November 2025, indicating an established mechanism for future registered transactions if the company chooses to utilize it.

Market Pulse Summary

This announcement highlights ATAI’s transition of BPL‑003 into a dual Phase 3 program in TRD, buildi...

Analysis

This announcement highlights ATAI’s transition of BPL‑003 into a dual Phase 3 program in TRD, building on Phase 2b data showing rapid, durable antidepressant effects and an open‑label extension strategy. Management also reaffirmed a cash runway into early 2029 and outlined additional catalysts such as VLS‑01 Phase 2 topline in H2 2026. Investors may monitor Phase 3 design execution, regulatory interactions, and upcoming readouts across the pipeline.

Key Terms

breakthrough therapy designation, phase 2b, treatment-resistant depression, end-of-phase 2 meeting, +4 more

8 terms

breakthrough therapy designation regulatory

"BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

phase 2b medical

"supported by positive Phase 2b results in treatment-resistant depression"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

treatment-resistant depression medical

"positive Phase 2b results in treatment-resistant depression"

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

end-of-phase 2 meeting regulatory

"following a successful End-of-Phase 2 meeting with the FDA"

An end-of-phase 2 meeting is a formal discussion between a drug developer and a regulatory agency to review mid-stage clinical results and agree on the plan and requirements for the larger, final tests needed for approval. It matters to investors because the meeting can clarify what evidence regulators will require, shape the cost and timeline for the next phase, and reduce uncertainty about whether a drug can advance toward market — like a checkpoint that determines whether a project gets the green light to move to the next, expensive stage.

phase 3 medical

"advancement of BPL‑003 toward Phase 3 initiation in Q2 2026"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

randomized, double-blind, placebo-controlled medical

"a 12‑week randomized, double‑blind, placebo‑controlled core study"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

open-label extension medical

"followed by a 52‑week open‑label extension allowing individualized retreatment"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

interventional psychiatry medical

"aligned to existing interventional psychiatry workflows, including those currently used for Spravato"

Interventional psychiatry is a medical specialty that treats severe or treatment-resistant mental health conditions using targeted procedures and fast-acting therapies, such as controlled brain stimulation or brief infusion treatments, rather than only daily pills and talk therapy. For investors it matters because these procedures require specialized equipment, trained clinics, regulatory approvals and reimbursement pathways, creating distinct markets and revenue streams and affecting a company’s commercial and regulatory risk—think of it as precision tools opening new business lines in mental health care.

AI-generated analysis. Not financial advice.

• BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression
• Cash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studies
• Commercial readiness advancing with scalable treatment model aligned to existing interventional psychiatry workflows
• Continued pipeline progress, including positive Phase 2a results for EMP‑01 and expected Phase 2 topline for VLS-01 in H2 2026
• Replay and presentation materials available on AtaiBeckley’s investor website
  

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today highlighted key clinical, regulatory, and operational milestones from its 2026 Virtual Investor Day, including the advancement of BPL‑003 (mebufotenin benzoate nasal spray) toward Phase 3 initiation in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA.

BPL-003, which holds Breakthrough Therapy Designation, is supported by positive Phase 2b results in treatment-resistant depression (TRD), demonstrating rapid antidepressant effects at Day 2, durable improvements through eight weeks, and higher response and remission rates following an optional second dose in the open-label extension.

The Company also reaffirmed its cash runway into early 2029, provided updates on its commercial readiness strategy, and outlined continued pipeline progress, including recently announced positive Phase 2a results for EMP‑01 and its expectation that VLS-01 will deliver Phase 2 topline data in H2 2026.

Advancing BPL-003 Towards Phase 3 in Treatment-Resistant Depression
A central focus of the event was the continued advancement of BPL‑003 toward Phase 3 studies in TRD. Following a successful End‑of‑Phase 2 meeting with the FDA, the Company remains on track to initiate two parallel Phase 3 studies – ReConnection-1 and ReConnection-2 - in Q2 2026. These pivotal trials will include a 12‑week randomized, double‑blind, placebo‑controlled core study, followed by a 52‑week open‑label extension allowing individualized retreatment based on pre‑specified criteria.

“BPL-003 has demonstrated rapid, durable antidepressant effects, and the FDA’s supportive End-of-Phase 2 feedback enables us to advance into two parallel Phase 3 trials beginning in Q2 2026,” said Srinivas Rao, Co-Founder and CEO. “With Breakthrough Therapy Designation and a robust pivotal design, we believe BPL‑003 has the potential to meaningfully reshape the treatment landscape for TRD.”

Commercial and Operational Readiness
Another key theme of the Investor Day was AtaiBeckley’s continued advancement of its commercial readiness strategy for BPL‑003, which is designed to integrate seamlessly into existing interventional psychiatry workflows, including those currently used for Spravato^®. The Company outlined a scalable treatment model that prioritizes patient convenience and safety, without requiring in‑session psychotherapy, enabling clinics to efficiently incorporate BPL‑003 within established care pathways.

BPL‑003 is supported by positive Phase 2b topline results, which demonstrated:

• rapid antidepressant effects at Day 2 from a single dose
• durable improvements maintained for up to eight weeks
• increased response and remission rates sustained for a further eight weeks following a second dose in the OLE
  

Kavita Panke, SVP of New Product Planning and Early Commercial Development, emphasized the potential operational advantages of the therapy: “Our goal is to make BPL‑003 realistic and accessible in everyday clinical practice. People need treatments that work quickly, are durable, and don't require them to reorganize their lives. BPL-003’s short treatment window and intermittent dosing regimen could give clinics a practical and scalable way to reach far more patients.”

Expert Perspectives on Mental Health Treatment Needs
The event closed with a roundtable discussion featuring:

• Dr. Peter Hendricks, Clinical Psychologist and Professor at the University of Alabama at Birmingham School of Public Health
• Dr. David Feifel, Professor Emeritus of Psychiatry at the University of California, San Diego, Founder and President of the Kadima Neuropsychiatry Institute, and consultant to AtaiBeckley
• Dr. Samuel Wilkinson, Associate Professor of Psychiatry at Yale School of Medicine
  

The discussion explored several key themes shaping the future of TRD and interventional psychiatry, including practical barriers to care, treatment duration and dosing paradigms, clinic infrastructure readiness, and the evolving positioning of new therapies relative to current standards of care.

The external experts highlighted how shorter, streamlined in‑clinic experiences and intermittent dosing regimens may meaningfully expand patient access while preserving strong clinical impact. They also noted that the current interventional psychiatry infrastructure - strengthened in recent years through broader adoption of treatments like Spravato^® - is increasingly well-positioned to support next-generation therapies such as BPL-003.

Replay and Materials
Presentation slides and a replay of the Investor Day are available on the investor section of the AtaiBeckley website, under Events.

About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; expectations regarding the outcome of regulatory discussions regarding the development of BPL003; expectations regarding the advancement into Phase 3 studies in adults with TRD and related milestones; expectations regarding the design of the Phase 3 program; and the potential benefits of BPL-003 for patients with TRD.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information:
Investors:
Jason Awe, PhD
VP, Investor Relations
IR@ataibeckley.com

Media:
Charlotte Chorley
Associate Director, Communications
PR@ataibeckley.com

FAQ

When will AtaiBeckley (ATAI) start Phase 3 trials for BPL-003?

The company plans to initiate two parallel Phase 3 trials in Q2 2026. According to the company, this follows a successful End-of-Phase 2 meeting with the FDA and supports the pivotal ReConnection-1 and ReConnection-2 designs.

What clinical results supported AtaiBeckley’s move of BPL-003 toward Phase 3?

BPL-003 showed rapid antidepressant effects by Day 2 and durable improvements through eight weeks. According to the company, Phase 2b also reported higher response and remission after an optional second dose in the open-label extension.

What is the regulatory status of BPL-003 (ATAI) for treatment-resistant depression?

BPL-003 currently holds Breakthrough Therapy Designation. According to the company, FDA End-of-Phase 2 feedback was supportive and enabled the planned Phase 3 initiation in Q2 2026.

How long is AtaiBeckley’s cash runway after the 2026 Investor Day update?

The company reaffirmed cash runway into early 2029. According to the company, this runway factors in planned parallel Phase 3 programs and near-term development activities.

What upcoming pipeline milestones should ATAI investors watch in 2026?

Investors should watch Phase 3 start for BPL-003 in Q2 2026 and VLS-01 Phase 2 topline expected in H2 2026. According to the company, EMP-01 has reported positive Phase 2a results already.